Proteros, co-founder of Rodin Therapeutics, announces Rodin´s acquisition by Alkermes

Proteros, co-founder of Rodin Therapeutics, announces Rodin´s acquisition by Alkermes

Munich, Germany, November 28, 2019. Proteros biostructures GmbH today announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland. Rodin has been co-founded by Proteros in 2013. Rodin´s security holders will receive an upfront payment of $100 million plus milestone payments.

 

For more information please visit

https://investor.alkermes.com/news-releases/news-release-details/alkermes-completes-acquisition-rodin-therapeutics

https://rodintherapeutics.com/press_releases/alkermes-to-acquire-rodin-therapeutics/

 

Download PDF